A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Clinical trial NCT06939452 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT06939452

Sponsor

Yongxu Jia

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2023-06-07

Primary completion

2026-06-01

Enrollment

37

View on ClinicalTrials.gov